共 50 条
A 2020 update on liver transplant for hepatocellular carcinoma
被引:16
|作者:
Finotti, Michele
[1
]
Vitale, Alessandro
[1
]
Volk, Michael
[2
]
Cillo, Umberto
[1
]
机构:
[1] Padova Univ Hosp, Dept Surg Oncol & Gastroenterol, Hepatobiliary Surg & Liver Transplantat Unit, Padua, Italy
[2] Loma Linda Univ Hlth, Div Gastroenterol & Hepatol, Loma Linda, CA USA
关键词:
Benefit Models;
downstaging;
hepatocellular Carcinoma;
liver transplantation;
primary Liver Transplant;
salvage Liver Transplant;
transplant benefit;
TO-LYMPHOCYTE RATIO;
ALPHA-FETOPROTEIN;
MICROVASCULAR INVASION;
SURVIVAL BENEFIT;
WAITING-LIST;
TRANSARTERIAL CHEMOEMBOLIZATION;
SALVAGE TRANSPLANTATION;
LOCOREGIONAL THERAPY;
SELECTION CRITERIA;
MILAN CRITERIA;
D O I:
10.1080/17474124.2020.1791704
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Introduction Hepatocellular carcinoma is the most frequent liver tumor and is associated with chronic liver disease in 90% of cases. In selected cases, liver transplantation represents an effective therapy with excellent overall survival. Area covered Since the introduction of Milan criteria in 1996, numerous alternative selection systems to LT for HCC patients have been proposed. Debate remains about how best to select HCC patients for transplant and how to prioritize them on the waiting list. Expert opinion The selection of the best scoring system to propose in the context of LT for HCC is far to be identified. In this review, we analyze and categorize the various selection systems, assessing their roles in the different decisional phases.
引用
收藏
页码:885 / 900
页数:16
相关论文